Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teprotumumab plus reduced-dose glucocorticoids vs standard therapies in moderate-to-severe active thyroid eye disease
ChiCTR2500114188Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of teprotumumab and methylprednisolone in Graves Orbitopathy (GO) (3 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoints: CAS score and Exophthalmos. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
teprotumumabmethylprednisolone
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2500114188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114188.